Sugentech Inc.
Financials
Valuation Metrics
Sugentech Inc.'s Market Cap is ₩680B. At end of 2025 it was ₩1028B. Ranked #1478 of 2,410 in KR market (top 61%), #848 of 1,631 on KOSDAQ (top 52%), #55 of 94 in Health Care Equipment & Services (top 59%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 67.98B KRW | KR#1,478/2,410 Sec#55/94 |
| Revenue | 9.78B KRW | KR#2,284/2,410 Sec#81/94 |
| Net Income | -23.15B KRW | KR—/2,410 Sec—/94 |
| Total Assets | 87.28B KRW | KR#1,883/2,410 Sec#58/94 |
| Net Assets | 68.56B KRW | KR#1,697/2,410 Sec#52/94 |
| Employees | 152 | KR#1,317/2,410 Sec#44/94 |
| Value | ||
| P/B | 0.99x | KR#1,547/2,410 Sec#45/94 |
| P/S | 6.95x | KR#2,234/2,410 Sec#78/94 |
| Profitability | ||
| ROE | -33.77% | KR#2,205/2,410 Sec#80/94 |
| ROA | -26.53% | KR#2,281/2,410 Sec#85/94 |
| Op. Margin | -192.84% | KR#2,321/2,410 Sec#85/94 |
| Revenue Growth | -15.96% | KR#2,055/2,410 Sec#86/94 |
| Financial Health | ||
| Debt Ratio | 27.30% | KR#530/2,410 Sec#29/94 |
| Total Debt | 11.50B KRW | KR#1,568/2,410 Sec#48/94 |
| Cash | 9.96B KRW | KR#1,698/2,410 Sec#56/94 |
| Current Ratio | 9.11x | KR#118/2,410 Sec#12/94 |
| Performance | ||
| 1Y Return | -38.20% | KR#1,652/2,410 Sec#56/94 |
| 1M Return | -11.74% | KR#1,042/2,410 Sec#41/94 |
| From 52W High | -50.79% | KR#1,176/2,410 Sec#44/94 |
| 1Y MDD | -52.99% | KR#1,087/2,410 Sec#40/94 |
| Trading | ||
| Volume | 23,270 shares | KR#1,217/2,410 Sec#49/94 |
| Trading Value | 94.6M KRW | KR#1,346/2,410 Sec#54/94 |
| Foreign Own. | 2.26% | KR#1,536/2,410 Sec#55/94 |
| Per Share | ||
| EPS | -1,383 KRW | KR—/2,410 Sec—/94 |
| BPS | 4,095 KRW | KR#1,660/2,410 Sec#43/94 |
Company Info
Established in 2011, the company achieved KONEX listing in 2016 and KOSDAQ transfer listing in 2019, with its main business being the research and development, manufacturing, and sales of in vitro diagnostic medical devices. It commercializes multiple immunoassay blots based on BIO/NANO/IT/A.I fusion technology and offers TRF and fluorescence-based quantitative analysis products for point-of-care diagnostics. In digital healthcare, Sugentech launched the nation's sole digital device for female hormone diagnosis, expanding into the health & beauty category to evolve into a comprehensive wellness platform. Sugentech is headquartered in Yuseong-gu, Daejeon Metropolitan City.